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Purpose: This study was designed as a multicenter, random-
ized, open-label study to evaluate the efficacy and tolerability 
of ClotinabTM. We expected to obtain same results as with 
ReoProⓇ in improving ischemic cardiac complications in 
high-risk patients who were about to undergo percutaneous cor-
onary intervention (PCI). Patients and Methods: Patients of 19 
- 80 years of age with acute coronary syndrome (ACS) who 
were about to undergo PCI were enrolled. After screening and 
confirmation of eligibility, patients were randomly assigned to 
different groups. ClotinabTM was given to 84 patients (58.7 ± 
10.6 years, M : F = 68 : 16) and ReoProⓇ (59.0 ± 10.5 years, 
M : F = 30 : 10) was given to 40 patients before PCI. The pri-
mary efficacy endpoint was the onset of major adverse cardiac 
event (MACE) within 30 days from day 1. The tolerability end-
points were assessed based on bleeding, thrombocytopenia, 
change in Hb/Hct, human antichimetric antibody development, 
and adverse events. Results: The number of ClotinabTM patients 
experiencing MACE was 0 out of 76 per protocol (PP) patients. 
The MACE rate was 0%, and its 95% exact CI was [0.00 - 
4.74%]. A major bleeding event developed in 3 patients in the 
ReoProⓇ group. The probability of MACE onset in ClotinabTM 
was estimated to be less than 5%. There was no clinically sig-
nificant result in tolerability variables. Conclusion: ClotinabTM 
is an effective and safe medicine in preventing ischemic car-
diac complications for high-risk patients who will receive PCI.
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INTRODUCTION
Platelet-mediated thrombosis accounts for the 
pathophysiology of acute coronary syndrome 
(ACS).1,2 In the treatment of ACS, intravenous 
platelet glycoprotein (GP) IIb/IIIa receptor 
antagonists for platelet aggregation may reduce 
the risk of ischemic complications.3-7 Therefore, in 
the management of ACS, platelet GP IIb/IIIa 
receptor inhibitors have been developed as a 
promising therapy for the reduction of coronary 
events and the improvement of clinical outcomes. 
Abciximab, a platelet GP IIb/IIIa receptor blocker, 
was developed by Coller in 1985 and named 7E3.8 
Abciximab is a chimeric human monoclonal 
antibody and binds to platelet surface GP IIb/IIIa 
receptors competitively with adhesive molecules, 
such as fibrinogen and von Willebrand factor, and 
blocks the final stage of platelet aggregation.9
ClotinabTM a product manufactured by ISU 
ABXIS Co., Ltd, was produced by inserting anti- 
platelet GP IIb/IIIa DNA into a Chinese hamster’s 
ovary cell. Since it contains the same active 
ingredient as ReoProⓇ, ClotinabTM is expected to 
have the same efficacy as ReoProⓇ as a platelet GP 
IIb/IIIa receptor inhibitor. Therefore, the aim of 
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this trial was to evaluate the efficacy and 
tolerability of ClotinabTM as an investigational 
drug and prevent ischemic cardiac events in 
high-risk patients scheduled to undergo PCI.
PATIENTS AND METHODS
Patients
Korean men and women between 19 - 80 years 
of age with ACS meeting 1 of the following 
conditions and who were scheduled to undergo 
PCI were enrolled: 1) Patients with ischemic ST 
change in the electrocardiogram as well as 
refractory to drug treatment in resting phase or 
with recurrent angina pectoris; 2) Post-infarction 
angina patients within 7 days from acute 
myocardial infarction (AMI) attack refractory to 
drug treatment with ischemic ST change in the 
electrocardiogram; 3) Acute Q-Wave myocardial 
infarction (MI) within 12 hours after the attack 
that required direct intervention procedures; 4) 
Acute Q-wave myocardial infarction within 12 
hours after the attack that required another rescue 
intervention after failure to thrombolytic therapy; 
and 5) Classification of vascular lesions according 
to the American College of Cardiology/American 
Heart Association (ACC/AHA) criteria defined by 
angiography.10
- Two type B lesion characteristics
- One type C lesion characteristic
- Females aged over 65 with one type B lesion 
characteristic 
- Diabetes with one type B lesion characteristic
 
Exclusion criteria
Patients with any of the following were excluded 
from the study: those in which PCI could not be 
performed within 24 hours from receiving the 
investigational product or occlusion of the left 
main coronary artery was ≥ 50% and bypass 
surgery was necessary. In addition, subjects with 
a culprit lesion in the bypass graft; history of 
major surgery, trauma, or retinal hemorrhage; 
significant gastrointestinal or genitourinary bleeding 
in the previous 6 weeks; cerebrovascular attack in 
the past 2 years or a cerebrovascular attack with 
a significant residual neurological deficit were 
excluded. Patients who required oral antico-
agulants during the trial; those who had been 
administrated oral anticoagulants in the past 7 
days; severe uncontrollable hypertension (systolic 
blood pressure > 180 mmHg or diastolic blood 
pressure > 100 mmHg); thrombocytopenia (< 100,000 
cells/mL); hypersensitivity to the test drug or the 
murine protein; history of hypersensitivity; 
intracranial neoplasm, arteriovenous malformation; 
aneurysm; history or diagnosis of vasculitis; renal 
insufficiency (the level of serum creatinine was 2 
times higher than the upper limit of normal of 
each center); or hepatic disorder (AST, ALT was 
three times higher than the upper limit of normal) 
were excluded. Pregnant women, alcoholics, drug 
abusers, patients who could not take anti-platelet 
drugs, and those who might have died of causes 
other than cardiac disease during the trial were 
also removed from the study.
Study design
This trial was conducted prospectively at 3 
medical centers in Korea from May 2005- 
December 2005 in 2 stages. The first stage was a 
single-arm, multicenter, open-label study of 
ClotinabTM. Thirty eligible patients were enrolled 
in the first stage. The original design was to 
evaluate efficacy and safety of ClotinabTM in the 
first stage. If the MACE rate was statistically 
significantly below 20%, the trial was to enter the 
second stage for comparison to ReoProⓇ. The 
second stage was a randomized multicenter open- 
label clinical trial with 40 patients to be assigned 
to the ClotinabTM group and 30 to the ReoProⓇ 
group. Although patients in the ClotinabTM group 
were recruited over two stages, the patients who 
were receiving ClotinabTM were considered as one 
group because there was no time break between 
the first and second stage and no protocol change 
between stages. 
During the initial screening, patients underwent 
complete physical examinations, baseline electro-
cardiograms, and laboratory assessments. They 
were randomly assigned into 2 groups according 
to a computer-generated allocation schedule. A 
randomization list was made using a block 
randomization method. To create a 4 : 3 allocation 
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ratio between the treatment and control groups, a 
block of size 7 was used for each center. The size 
of the block was not specified in the protocol or 
known to investigators. 
After the screening and confirmation of the 
eligibility of patients, those who signed written 
consent forms were randomly assigned to one of 
the groups prior to the procedure, administration 
of the investigational product, and treatment by 
PCI on day 1. One group received 0.25 mg/kg of 
ClotinabTM IV bolus 10 minutes to 6 hours prior 
to PCI, followed by an infusion of 0.125 mg/kg/ 
min (Max 10 μg/min) dissolved in sterile saline of 
0.9% or 5% dextrose followed for 12 hours. The 
other group received 0.25 mg/kg of ReoProⓇ IV 
bolus 10 minutes to 6 hours prior to PCI, followed 
by an infusion of 0.125 mg/kg/min (Max 10 μg/ 
min) dissolved in sterile saline of 0.9% or 5% 
dextrose followed for 12 hours. After the pro-
cedure, subjects remained in the intensive care 
units for observation. At least 2 hours before PCI 
in both groups, 200 mg of aspirin was administered 
orally, followed by oral administration of 100 mg/ 
day. In addition to aspirin, a loading dose of 300 
mg and maintenance dose of 75 mg/day of 
clopidogrel were given. 
On day 30 after discharge, patients visited the 
hospital for safety and efficacy assessments. 
During the clinical visit, subjects were assessed by 
all clinical and laboratory measures, to unravel, 
the likelihood of a causal relationship between the 
study and the study drug ("definitely related", 
"probably related", "possibly related", "probably 
not related", "definitely not related", and 
"unknown"), and they were categorized by the in-
tensity of clinical adverse experiences (CAEs). The 
institutional review board and ethics committee at 
each participating center approved the protocol, 
and written consent forms were obtained from all 
patients.
Efficacy assessments
The primary efficacy endpoint was the onset of 
MACE within 30 days from the study drug 
administration following PCI. MACE included 
death related to heart disease, recurrence of MI, 
and emergency revascularization. We classified 
the cause of death to either "cardiovascular causes" 
or "non-cardiovascular causes" (If non-cardiovas-
cular causes could not clearly be established, the 
cause of death was classified to "cardiovascular 
causes"). The recurrence of MI was categorized as 
ST-elevation MI (STEMI) or non-ST-elevation MI 
(NSTEMI) [NSTEMI; CK-MB > 3 times the upper 
limit of normal value and increase of > 50% in the 
second sample over the first sample when two 
samples were collected at two different times]. A 
return to the catheterization laboratory for 
emergency revascularization to treat recurrent 
ischemia was considered as a primary event. A 
scheduled PCI (staged procedures) nor elective 
surgery to treat pre-existing multivessel disease was 
considered primary events. The secondary efficacy 
endpoint was a change in the electrocardiogram 
[New change in electrocardiogram was decided 
by investigator’s decision about the ECG result], 
indicating myocardial ischemia. 
Tolerability assessments
Tolerability endpoints were assessed by bleeding, 
thrombocytopenia, changes in Hb/Hct, HACA 
(human antichimetric antibody) development, and 
adverse events. (1) Bleeding: According to TIMI 
criteria,11 bleeding was categorized into "major 
bleeding". "minor bleeding", or "insignificant 
bleeding". (2) Thrombocytopenia: The details were 
described for patients whose platelet count was < 
100.000 and platelet count decreased by ≥ 25% 
compared to baseline count. (3) Change of 
Hb/Hct: (4) HACA development: Frequency and 
proportion were presented to patients showing a 
positive response to HACA development by 
group. (5) Adverse events: All adverse events 
were coded. Frequency and proportion by these 
codes were generated in 2 groups. The frequency 
was calculated by group for adverse events that 
were related to the study drug ("definite", 
"probable", "possible") and not ("improbable", 
"none", "unknown"). Frequency and proportion 
(95% exact CI) were presented for the number of 
adverse event and the number of subjects in 
which adverse events occurred at least once. 
Manufacturing process of ClotinabTM
The active substance abciximab is produced in 
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recombinant Chinese Hamster Ovary (CHO) cells 
using a serum-free media. The master cell bank 
(MCB), working cell bank (WCB), and end of 
production cells were sufficiently characterized. 
The MCB and WCB were adopted to grow in 
serum-free media. The manufacturing process of 
the active ingredient starts with the thawing and 
expansion of cells from the MCB or WCB derived 
from the MCB. Cells were expanded using a flask 
and fermenters. After harvesting, different 
chromatographic steps were used for purification. 
With affinity chromatography, unwanted protein 
and potential endotoxin contaminants were 
removed. Cation exchange chromatography 
removes antibody aggregates and fragment and 
CHO impurities. Anion exchange chromatography 
is intended to separate DNA, endotoxins, and 
retroviruses if present. With hydrophobic interac-
tion, the chromatography removes antibody 
aggregates and fragments and CHO proteins. 
 
Statistical analysis
A 1-sided significance test was applied to the 
primary efficacy endpoint at α = 0.05. All other 
significance tests were 2-sided at α = 0.05, and the 
efficacy analysis was the PP analysis. All 
statistical analyses were carried out by SASⓇ 
(Version 9.1, SAS institute, Cary, NC, USA). Exact 
confidence intervals were computed by StatXact 
(version 4.0, Cytel Software Corp). Continuous 
variables were compared using t-test or Wilcoxon 
rank sum test by treatment group. Categorical 
variables were compared using chi-square test or 
Fisher’s exact test. For the primary endpoint, a 
non-inferiority analysis of the difference in MACE 
from baseline to day 30 between both study 
groups was assessed. Chi-square tests or Fisher's 
exact tests were performed to compare ClotinabTM 
and ReoProⓇ. Fisher's exact tests were performed 
to find the differences between the two groups. 
McNemar's tests were used to determine if the 
changes in electrocardiogram from pre- to post- 
administration were significant. 
Any statistical significance tests would be 
probably underpowered if we make a direct 
comparison between two drugs. Therefore, we 
planned a non-inferiority trial, and unplanned 
posthoc statistical significance tests were performed 
on the difference in various parameters between 
ClotinabTM group and ReoProⓇ group. 
Sample size estimation
ClotinabTM has same active ingredient as ReoProⓇ 
and is supposed to have a similar effect. The 
clinical trial was designed to prove that event rate 
of the primary efficacy endpoint of ClotinabTM 
was below 20%. This value of 20% was deduced 
from previous clinical trials.3,9,12-14 The following 
are the statistical null hypothesis and alternative 
hypothesis in this trial on ClotinabTM.
H0: p ≥ 0.2 versus HA: p < 0.2 
It is assumed that the event rate is more than 
0.2. If the null hypothesis was rejected by this 
trial, it was concluded that the event rate of 
ClotinabTM was less than 0.2. The previous clinical 
trial set the event rate of 9%.15 Data distributed 
binomially, sample size, and critical value were 
obtained to satisfy significance level and power 
exactly at 0.05 and 0.8, respectively. The efficacy 
interpretation followed the decision rule. In the 
analysis of PP population, if 9 or fewer patients 
among 76 subjects who were treated with 
ClotinabTM experienced MACE, the MACE rate 
was estimated to be below 20% and ClotinabTM 
was considered to be effective. In FAS (Full 
analysis set, n = 83) and ITT (Intention-to-Treated, 
n = 84) population, if 10 or fewer patients 
experienced MACE, the MACE onset rate was 
estimated to be below 20% and ClotinabTM was 
considered to be effective. If the number of MACE 
patients was more than the defined number in 
each population, the efficacy of ClotinabTM was 
evaluated after adjusting the critical value based 
on the MACE rate in ReoProⓇ. 
RESULTS
Patient characteristics
A total of 124 patients were screened for this 
trial at 3 medical centers. First, 31 patients were 
given ClotinabTM treatment without randomization. 
Afterward, 93 patients were admitted and 
randomized into the ClotinabTM (53) and ReoProⓇ 
(40) groups. Out of the 124 subjects screened, one 
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Table 1. Subject Demographics
Variables
ITT population (n = 124)
ClotinabTM (n = 84) ReoProⓇ (n = 40)
Age (yrs)  58.7 ± 10.6  59.0 ± 10.5
Sex Gender (M : F)  68 : 16  30 : 10
Current smoker, n (%)  30 (35.7%)  13 (32.5%)
Hypertension, n (%) 378 (72.4%) 308 (85.3%)
Diabetes, n (%)  18 (21.4%)  10 (25.0%)
SBP (mmHg) 124.39 ± 20.20 127.08 ± 19.71
DBP (mmHg) 73.57 ± 9.71  72.43 ± 11.80
RBC count  4.40 ± 0.49  4.42 ± 0.51
Platelet count 214K ± 44.0 236K ± 52.6
T. cholesterol (mg/dL) 172.3 ± 43.4 169.9 ± 32.8
Fasting glucose (mg/dL) 128.25 ± 56.79 128.90 ± 59.21
ITT, intention-to-treated; SBP, systolic blood pressure; DBP, diastolic blood pressure; T. cholesterol, total cholesterol.
subject was excluded before the treatment started, 
because the patient was found to be ineligible. 
After the study drugs were administered and PCI 
was performed on the 123 patients, one ClotinabTM 
subject withdrew consent and left the trial. The 
disposition status of 124 patients is shown in Fig. 1.
Out of the 124 subjects, including 31 ClotinabTM 
patients from stage 1, 84 subjects received 
ClotinabTM and 40 received ReoProⓇ The ITT set 
consisted of all 124 patients and the FAS consisted 
Fig. 1. Disposition of patients There 
were 12 subjects with major protocol 
deviation. One1 had CABG treatment 
after PCI failure; 5 ClotinabTM patients2
who completed the trial were considered
to be major protocol deviations; of 5 
ClotinabTM patients, 4 did not clear 
exclusion criteria; and 1 patient came 
for the follow-up visit on day 10 instead
of day 30. Two3 patients dropped out 
of the study, 1 subject withdrew consent
on day 2, and 1 randomized subject 
(RDZ) was dropped because of a 
screening failure (SF). Four ReoProⓇ 
patients4 were considered major 
protocol violations, 3 subjects did not 
clear exclusion criteria, and 1 subject 
occurred an accidental disconnection 
of the IV line during IV administration 
of study drug.
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Table 2. Distribution of Subjects by Disease (can select more then one item)
ITT population (n = 124)
p value
ClotinabTM (n = 84) ReoProⓇ (n = 40)
Ischemic ST change in electrocardiogram plus being refractory 
to drug treatment in resting phase or with recurrent angina 
pectoris 
18  8 0.855†
Ischemic ST change in electrocardiogram plus post-infarction 
angina patients within 7 days after myocardial infarction 
attack that is refractory to drug treatment 
16  6 0.581†
Acute Q-Wave myocardial infarction within 12 hours after 
the attack that requires direct intervention procedures 
 6  4 0.726‡
Acute Q-Wave myocardial infarction within 12 hours after 
the attack that requires another procedure after failure of 
thrombolytic therapy 
 4  2 1.000‡
Two type B lesion characteristics* 29 11 0.434†
One type C lesion characteristic* 45 22 0.881†
Females aged over 65 with one type B lesion characteristic*  4  1 1.000‡
Diabetics with one lesion type B characteristic*  6  6 0.199‡
ITT, intention-to-treated.
*The coronary artery stenosis ACC/AHA classification defined by angiography.10 
†p value from chi-square test.
‡p value from Fisher’s exact test.
of 123 (ClotinabTM: 83 patients, ReoProⓇ: 40). The 
PP set consisted of 112 patients (ClotinabTM: 76 
patients, ReoProⓇ: 36), PP analysis was the main 
method used to evaluate the efficacy of the drug 
and FAS analysis was used to determine the 
tolerability of the study drug. Table 1 gives the 
general characteristics of patients included in the 
study. The distribution of subjects by disease 
entity is shown in Table 2. There was no significant 
difference between the two study groups.
Efficacy results
The primary efficacy endpoint was the onset of 
MACE within 30 days from the study drug 
administration following PCI. Table 3 shows the 
primary results of this trial. The number of 
ClotinabTM patients experiencing MACE was 0 out 
of 76 PP patients. The MACE rate was 0.00%, and 
its 95% exact CI was (0.00 - 4.74%). The upper 
confidence bound was less than 5%. The number 
of ReoProⓇ patients experiencing MACE was 2 
out of 36 PP patients. The observed MACE rate 
was 5.56%, and its 95% exact CI was (0.68 - 
18.66%). The upper confidence bound was below 
20%. The ITT population analysis showed little 
variation from the PP analysis. None of 84 
ClotinabTM subjects experienced MACE. The 
observed MACE rate was 0.0% and its 95% exact 
CI was (0.00 - 4.30%). Two out of 40 ReoProⓇ 
subjects experienced MACE. The observed MACE 
rate was 5.00% and its 95% exact CI was (0.61 - 
16.92%). Upon analyses of PP, ITT, and FAS 
populations, it was concluded that ClotinabTM was 
effective in preventing MACE. The upper bound 
of 95% CI was all less than 5% regardless of the 
analysis population, indicating that the MACE 
rate among patients undergoing PCI will be less 
than 5% if they are also treated with ClotinabTM. 
In the ReoProⓇ group, the upper bound of 95% 
CI was about 16.9 - 18.7% depending on the 
analysis population (ITT analysis: 16.9%, PP 
analysis: 18.7%). This indicates that less than 20% 
of patients undergoing PCI will experience MACE 
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Table 3. Primary Efficacy Endpoint: Major Adverse Cardiac Event Between ClotinabTM and ReoProⓇ Groups 
Treatment group MACE In hospital Day 30 Total Cut-off value*
ClotinabTM
 ITT set Death due to cardiac disease 0 0 0
(n = 84) Recurrence of MI 0 0 0
Emergency revascularization 0 0 0
Total 0 0 0 ≤ 10
PP set Death due to cardiac disease 0 0 0
(n = 76) Recurrence of MI 0 0 0
Emergency revascularization 0 0 0
Total 0 0 0 ≤ 9
ReoProⓇ 
ITT set Death due to cardiac disease 0 2 (5.00%) 2 (5.00%)
(n = 40) Recurrence of MI 0 0 0
Emergency revascularization 0 0 0
Total 0 2 (5.00%) 2 (5.00%)
PP set Death due to cardiac disease 0 2 (5.56%) 2 (5.56%)
(n = 36) Recurrence of MI 0 0 0
Emergency revascularization 0 0 0
Total 0 2 (5.56%) 2 (5.56%)
MACE, major adverse cardiac event; ITT, intention-to-treated; PP, per protocol.
*The cut-off value comes from decision rule (decision rule is explained in the section of sample size estimation). 
if treated with ReoProⓇ.
The secondary efficacy endpoint was a change 
of electrocardiogram that indicated myocardial 
ischemia. One ClotinabTM patient showed changes 
at 24 h and on day 3. None of the other ClotinabTM 
subjects showed new changes. One ReoProⓇ 
patient showed changes at 12 h, 24 h, and on day 
3. None of the other ReoProⓇ patients showed any 
changes. 
The drop of the status of ischemia rate in the 
ClotinabTM group from 37.3% at baseline to 
20.0% on day 30 was statistically significant by 
the PP analysis (p < 0.001). The drop in the 
ReoProⓇ group from 48.6% to 21.2% was also 
statistically significant by the PP analysis (p = 
0.013). The electrocardiogram data in the ITT 
and the FAS populations revealed results similar 
to that of the PP population. Unplanned posthoc 
analyses showed that there was no significant 
difference in the electrocardiogram changes (data 
not shown) between the ClotinabTM and the 
ReoProⓇ groups.
Tolerability results
Based on TIMI criteria, no major bleeding 
occurred in ClotinabTM patients, but 3 subjects 
(7.50%) experienced major bleeding on ReoProⓇ. 
The number of subjects with minor bleeding was 
11 (13.25%) for ClotinabTM and 5 (12.50%) for 
ReoProⓇ. The number of subjects with clinically 
insignificant bleeding was 11 (13.25%) for ClotinabTM 
and 9 (22.50%) for ReoProⓇ. 
Based on TIMI criteria, the number of patients 
with overall bleeding showed no significant 
difference between ClotinabTM and ReoProⓇ at 
each time point (Table 4). However, a number of 
patients with major bleeding showed significant  
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Table 5. HACA Incidence Between ClotinabTM and ReoProⓇ Groups
HACA
FAS population (n = 123)
p value
ClotinabTM ReoProⓇ
Subjects (n) 83 40
Subjects with positive response (n)  6  1
Positive response rate (%) 7.2% 2.5% 0.426*
Exact 95% CI (2.70 - 15.07%) (0.06 - 13.16%)
HACA, human antichimetric antibody; FAS, full analysis set; CI, confidence interval.
*p value from Fisher’s exact test.
Table 4. Number of Patients with Bleeding Events
FAS population (n = 123)
p value
ClotinabTM (n = 83) ReoProⓇ (n = 40)
Major bleeding 0 (0.00%) 3 (7.50%) 0.033*
Minor bleeding 11 (13.25%)  5 (12.50%) 0.907†
Clinically insignificant bleeding 11 (13.25%)  9 (22.50%) 0.193†
FAS, full analysis set.
Number of patients with at least 1 bleeding event during the trial.
*p value from Fisher’s exact test.
†p value from chi-square test.
differences (p = 0.033). No significant results were 
noted in thrombocytopenia, change in Hb/ Hct, 
HACA.
Serious adverse events occurred in 7 subjects [3 
in ClotinabTM (3.61%), 95% exact CI (0.75 - 10.20%)], 
[4 in ReoProⓇ (10.00%), 95% exact CI (2.79 - 23.66%)]. 
Prolongation of existing hospitalization: 2 patients, 
life-threatening: 1 subject in ClotinabTM. Death: 2 
subjects, life-threatening: 2 subjects in ReoProⓇ. 
But we concluded that these 7 cases were not 
related to the study drug and there was no 
significant difference in SAE occurrence rate 
between ClotinabTM and ReoProⓇ (p = 0.152).
Sudden cardiac death occurred in two patients. 
One patient who had taken medication for 
diabetes mellitus and hypertension was treated 
with ReoProⓇ, followed by PCI. The subject died 
one week after discharge. The other patient was 
treated with ReoProⓇ and PCI for STEMI. He was 
admitted to the emergency room due to chest pain 
4 days after discharge. Cardiac arrest occurred, 
and cardiopulmonary resuscitation was performed 
but the subject died. The investigator concluded 
that these two events were definitely not related 
to the study drug. Of the life-threatening adverse 
events, there was a case of cardiac tamponade in 
the ReoProⓇ group during PCI, one case of 
cardiac tamponade in the ReoProⓇ group on day 
21 post-PCI, and one case of transient bradycardia 
with hypotension due to "no-reflow phenomenon" 
after stenting in the ClotinabTM group. Of the 
adverse events of prolongation of hospitalization, 
there was one case of dyspnea in the ClotinabTM 
group on day 2, and one case of urinary difficulty 
in the ClotinabTM group on day 23. All subjects, 
however, recovered and completed the study. We 
concluded that this was definitely not related to 
the study drug. The most frequent adverse events 
in the ClotinabTM and ReoProⓇ groups were 
related to general disorders and conditions of 
administration site. The most frequent adverse 
events related to PCI were wound secretion, catheter 
site hematoma, or catheter site hemorrhage in 
both treatment groups.
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Out of 83 subjects in the ClotinabTM and 40 
subjects in the ReoProⓇ groups, the number of 
subjects whose results were higher than the 
cut-off values or more than twice at 30 days after 
the administration, compared to the pre- 
administration in IgG screening, was 13 and 4 in 
the ClotinabTM and ReoProⓇ groups, respectively. 
After neutralization of the subjects who were 
selected by IgG screening, 6 subjects [7.2%, 95% 
exact C.I.(2.70 - 15.07%)] in the ClotinabTM group 
(83 subjects) were confirmed as HACA seropositive,  
and 4 among them were V-region and 2 were C- 
region. One patient [2.5%, 95% exact CI (0.06 - 
13.16%)] in the ReoProⓇ group (40 subjects) was 
confirmed as HACA seropositive and C-region. 
Unplanned posthoc analyses showed that there 
was no significant difference in HACA seroposi-
tive response rate between the ClotinabTM and 
ReoProⓇ groups(p = 0.426) (Table 5).
DISCUSSION
In this study, we demonstrated the efficacy and 
tolerability of ClotinabTM in improving ischemic 
cardiac complications in high-risk patients who 
were about to undergo PCI.
None of  84 patients in the ClotinabTM group 
experienced the primary efficacy endpoints of 
MACE. The same conclusion was also reached in 
the PP, ITT, and FAS populations. ClotinabTM is 
effective in preventing MACE. The upper bound 
of 95% CI was all below 5% regardless of the 
analysis population, indicating that the MACE 
rate among patients undergoing PCI will be less 
than 5% if treated with ClotinabTM. Only one 
ClotinabTM patient experienced a change in 
electrocardiogram. The rate of ischemia, indicated 
by electrocardiogram, in the ClotinabTM patients at 
day 30 dropped significantly by about 17% from 
the baseline depending on the PP analysis. None 
of the ClotinabTM patients experienced major 
bleeding event. Therefore, we can conclude that 
ClotinabTM is safe and effective in preventing 
MACE in high-risk patients undergoing PCI. 
In contrast, 2 out of 40 patients in the ReoProⓇ 
group experienced MACE during the study. The 
upper bound of 95% CI in the ReoProⓇ patients 
was about 16.9 - 18.7%, depending on the analysis 
population, indicating that less than 20% of the 
patients undergoing PCI will experience MACE if 
they are treated with ReoPro.Ⓡ Only one patient 
experienced a change of electrocardiogram. The 
rate of ischemia, indicated by electrocardiogram, 
in the ReoProⓇ group at day 30 dropped 
significantly by about 27% from the baseline, 
depending on the PP analysis. There was no 
clinically significant result noted in tolerability 
variables without a major bleeding event. Three 
ReoProⓇ patients experienced a major bleeding 
event. The major bleeding rate was significantly 
higher in the ReoProⓇ group than in the 
ClotinabTM group. Because this study was not 
designed to compare the efficacy or tolerability of 
ClotinabTM with ReoProⓇ in patients undergoing 
PCI, we cannot conclude which treatment is safer 
or more effective. Nevertheless, we can conclude 
that ClotinabTM is safe and effective in preventing 
MACE in patients undergoing PCI.
The effect of the platelet GP IIb/IIIa receptor 
blocker has been proven in numerous clinical 
trials, such as the EPIC trial,9 EPILOG trial,16 
PRAGON trial,17 PRISM trial,18 PRISM-PLUS trial,5 
and PURSUIT trial.6 Therefore, the use of GP 
IIb/IIIa inhibitor has become standard therapy for 
PCI in high-risk patients. The ACC/AHA recom-
mend the use of platelet GP IIb/IIIa inhibitors in 
patients undergoing PCI.19 The representative 
platelet GP IIb/IIIa receptor blockers currently 
used in clinical practice include abciximab (ReoProⓇ), 
which is a chimeric human-murine monoclonal 
antibody fragment; eptifibatide (Integrilin), which 
is a peptide; and Tirofiban (AggrastatⓇ) and 
Lamifiban, which are peptidomimetics.5,9,16,18,20-22 
The most potent antithrombotic effect has been 
documented with ReoProⓇ, because it has a 
prolonged half-life and binds to the vitronectin 
receptor (found on endothelial and smooth-muscle 
cells).23,24 Therefore, ReoProⓇ has the potential to 
influence the adhesion of platelets with endothelial 
cells and platelets with white cells. However, the 
selection of platelet GP IIb/IIIa receptor blockers 
is often based on the clinician's preference and 
cost consideration. Because of its relatively high 
cost, the use of ReoProⓇ is not an option for some 
patients. There are reports on the economics of GP 
IIb/IIIa inhibitor therapy. The PRICE (Prairie 
ReoProⓇ Versus Integrilin Cost Evaluation) trial 
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evaluated the differences between groups and 
concluded that eptifibatide was associated with 
lower in-hospital and 30-day costs compared to 
ReoProⓇ.25 By comparing abciximab and eptifiba-
tide, the PRICE study noted significant differences 
in hospitalization and acquisition costs despite 
comparable tolerability and effectiveness.26
There are unequivocal clinical benefits in using 
GP IIb/IIIa inhibitors to reduce the ischemic 
complications of PCI. TARGET27 demonstrated the 
benefit of abciximab, in ischemic outcomes 
ofpatients treated by PCI compared to tirofiban. 
Moreover, the meta-analysis on the different GP 
IIb/IIIa receptor blockers suggests clinical dif-
ferences among these drugs.28 
Because the economics of the GP IIb/IIIa 
inhibitor therapy are closely linked to drug 
efficacy and tolerability, the development of GP 
IIb/IIIa receptor blocker, which is not only 
biocompatible to ReoProⓇ in efficacy and tolerability 
but also low in cost, may be an affordable option. 
ClotinabTM, shown to be effective and safe in this 
study, may be used, in clinical practice, as a good 
substitute for ReoProⓇ because of its low cost. In 
conclusion, the probability of MACE onset in 
patients who use ClotinabTM is estimated to be 
less than 5%. There was no significant outcome in 
tolerability variables. Therefore, clotinabTM is an 
effective medicine in preventing ischemic heart 
complications for high-risk patients who undergo 
PCI. 
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